Overview

Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Open label, randomised, multicenter, superiority study for efficacy. Patients with histologically proven adenocarcinoma of the stomach or gastroesophageal junction without gross or microscopic evidence of residual disease after surgery with curative intent and fulfilling all the inclusion/exclusion criteria are eligible for this study.
Phase:
Phase 3
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research
Collaborators:
Aventis Pharmaceuticals
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Gruppo Oncologico del Nord-Ovest
Gruppo Oncologico Italiano di Ricerca Clinica
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Italian Trial in Medical Oncology
Oncotech
Southern Italy Cooperative Oncology Group
Treatments:
Cisplatin
Docetaxel
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin